



Clinicopathologic and Prognostic Features in Gallbladder Malignancies: Retrospective Analysis of 5206 Cases

Safra Kesesi Malignitelerinde Klinikopatolojik ve Prognostik Özellikler: 5206 Olgunun Retrospektif Olarak İncelenmesi

© Murat Ferhat Ferhatoğlu, © Kazım Şenol*, © Taner Kıvılcım, © Abdalcabbar Kartal, © Alp Gürkan

Okan University Faculty of Medicine, Department of General Surgery, İstanbul, Turkey

*Koç University Faculty of Medicine, Department of General Surgery, İstanbul, Turkey

Abstract

Aim: Gallbladder cancer is the sixth most common cancer of the gastrointestinal system. Clinical presentation may not be distinguished from cholelithiasis or cholecystitis and most patients are diagnosed intraoperatively or in the postoperative histologic examination. In this study, we aimed to investigate the association of incidentally detected gallbladder cancer with gallbladder premalignant lesions, age, gender, ultrasonography features and gallbladder stones.

Methods: Demographic and clinical characteristics and pathology results of 5206 patients who underwent cholecystectomy between January 2012 and December 2015 were evaluated retrospectively.

Results: Three thousand eight hundred and eighty four (74.6%) patients were female. Pathologic reports showed pre-malignant and malignant lesions in 102 (1.95%) cases. Metaplasia was significantly more common in females, while no significant difference was found in development of dysplasia and cancer between genders. Gallbladder stone was found to be a risk factor for the development of metaplasia. Gallbladder wall thickening and advanced age are the most important risk factors for gallbladder cancer.

Conclusion: Female gender and gallstone are important risk factors for the development of metaplasia. Advanced age, gallstone and gallbladder wall thickening on ultrasonography are the most important factors in the development cancer. Cholecystectomy should be kept in mind as the most effective method to prevent cancer development in elderly patients with gallbladder stones.

Keywords: Gallbladder carcinoma, gallstone, malignancy

Öz

Amaç: Safra kesesi kanseri, gastrointestinal sistemin en yaygın altıncı kanseridir. Klinik prezentasyon safra kesesi taşı veya kolesistitiden ayırt edilemez ve çoğu hasta intraoperatif veya postoperatif histolojik incelemede tanı alır. Bu çalışmada, insidental olarak tespit edilmiş safra kesesi kanserli olguların safra kesesi pre-malign lezyonları, yaş, cinsiyet, ultrasonografi özellikleri ve safra kesesi taşı ile ilişkisi araştırılmıştır.

Yöntemler: Ocak 2012-Aralık 2015 tarihleri arasında kolesistektomi uygulanan 5206 hastanın demografik ve klinik özellikleri, patoloji sonuçları retrospektif olarak değerlendirildi.

Bulgular: Hastaların 3884'ü (%74,6) kadındı. Patoloji raporlarında 102 (%1,95) olguda pre-malign ve malign lezyonlar olduğu tespit edildi. Metaplazi kadınlarda anlamlı olarak daha fazla iken, displazi ve kanser gelişimi arasında cinsiyete göre anlamlı bir fark bulunamadı. Safra kesesi taşı metaplazi gelişiminde bir risk faktörü olarak bulundu. Safra kesesi duvar kalınlaşmasının ve ileri yaşın safra kesesi kanseri gelişimi için en önemli risk faktörleri olduğu tespit edildi.

Sonuç: Metaplazi gelişiminde kadın cinsiyet ve taş varlığı önemli faktörlerdir. Ultrasonografide safra kesesi duvar kalınlaşması, ileri yaş, safra kesesinde taşı varlığı kanser gelişiminde en önemli faktörlerdir. Kolesistektomi, ileri yaşta safra kesesi taşı olan hastalarda kanser gelişimini önlemek için en etkili yöntem olarak akılda tutulmalıdır.

Anahtar Sözcükler: Safra kesesi kanseri, safra kesesi taşı, maligntite

Introduction

Gallbladder cancer (GBC) is the sixth most common cancer of the gastrointestinal system, with a worldwide annual incidence of 2.2 per 100.000 and 5-year mortality rate of 90%-95% (1,2).

Adenomatous polyps, porcelain gallbladder, high body mass index and obesity, chronic inflammation due to *Salmonella* and *Helicobacter* infections, smoking, pancreaticobiliary junction anatomy abnormality, primary sclerosing cholangitis, female sex, gallbladder stones, ethnicity, ulcerative colitis, adenomyomatosis, and age >65 are known risk factors for the development of GBC (3,4).

Clinical presentation may not be differentiated from cholelithiasis or cholecystitis, and most patients are diagnosed at the time of surgery or during postoperative histologic examination.

Accepted treatment strategy for Tis (*in situ* carcinoma) and T1a (tumor invasion to lamina propia) GBC is simple cholecystectomy (5). Cholecystectomy with regional lymph node dissection and wedge resection of the gallbladder bed with 3 cm margins is recommended for more advanced tumors because of the possibility of micro-metastases (6).

The present study aimed to investigate the association of incidentally detected GBC with premalignant lesions of the gallbladder.

Methods

In this retrospective study, 5206 patients, who underwent cholecystectomy in the department of general surgery at Bursa State Hospital between 2012 and 2015, were evaluated. The patients were analyzed according to demographic data and pathological reports. Age, sex, malignant lesions, premalignant lesions, stone presence and ultrasonography reports were evaluated. The study protocol was approved by the Ethics Committee of İstanbul Okan University, İstanbul (no: 94, date: 09 May 2018).

Statistical Analysis

SPSS for Windows 23.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Mean and standard deviation of numerical data were used in the study, and frequency and ratio were used in the presentation of categorical data. A chi-square test was used for categorical data, and ROC curve analysis was used to determine the predictive value of age and sex in the development of GBC. A p value of less than 0.05 was considered statistically significant.

Results

Of 5206 patients, 3884 (74.6%) were female and 1322 (25.4%) were male (male-to-female ratio=3:1), mean age was 52.81±14.15 years. Pathological reports

showed premalignant and malignant lesions (metaplasia, dysplasia, or carcinoma) in 102 (1.95%) patients. The prevalence and mean age for premalignant and malignant lesions are shown in Table 1.

ROC curve analysis for age of the patients showed that the predictive value of advancing age was the highest for the development of GBC (AUC=0.760, p<0.001) (Table 2).

Metaplasia was significantly more common in females (male-to-female ratio=3:10, p=0.022), whereas no significant relationship was found between sex and dysplasia (male-to-female ratio=8:10, p=0.167) and between sex and carcinoma (male-to-female ratio=7:10, p=0.173).

Presence of gallbladder stones was a risk factor for the development of metaplasia and carcinoma, however, it did not have an effect on the development of dysplasia (Table 3).

Table 1. Prevalence and mean age for premalignant and malignant lesions of the gallbladder

Lesion	n=102 (%)	Age (mean ± SD) years
Metaplasia	74 (64%)	54.18±13.5
Dysplasia	11 (9%)	54.63±14.2
Carcinoma	17 (15%)	70.79±10.1

SD: Standard deviation




Table 2. Age and gallbladder cancer predictive value

Area	Standard error	Asymptomatic Sig ^b	Confidence interval	
			Lower bound	Upper bound
0.760	0.067	0.000	0.630	0.891

^b: Predictive value of age for the development of GBC

Ultrasonography (US) results of 95 patients were evaluated (data of seven patients were missing) according to the thickening of the gallbladder wall and size and number of gallbladder stones. Increased thickening of the gallbladder wall was significantly more common in patients with GBC compared to metaplasia and carcinoma (Table 4).

Seventeen patients had the diagnosis of gallbladder carcinoma (0.32%). Of 17 carcinomas, 13 (76.4%) were in the corpus of the gallbladder and five had cystic duct invasion. Five were at the *in situ* stage (Table 5). All patients with cystic duct invasion had perineural and vascular infiltration. Overall survival of the patients with cystic duct invasion was 15.2±8.98 years.

Discussion

GBC is the twentieth most common cancer, and it is the most common cancer of the biliary tract, with 178.801 new cases and 142.823 deaths recorded in 2012 (2). Approximately 65% of GBC cases occur in less developed countries. Chile has the highest rate of GBC incidence, followed by Bolivia. Izarzugaza et al. (7) reported that the GBC incidence among

females and males in Chile between 2003 and 2007 was 17.1% and 7.3%, respectively (7). Geographical variations may affect the GBC incidence. The disease is more frequent in Central and South America which may be related to widespread Salmonella infection and aflatoxin B contamination in dried *Capsicum annuum* L. (or red chili peppers). Zhang et al. (8) reported that 0.19% of 10.466 patients who underwent laparoscopic cholecystectomy between 1999 and 2007 in China were diagnosed with GBC (Table 6) (8). Different incidence rates may be attributed to variations in ethnicity, geography, socioeconomic background, race and eating habits. In addition, inadequate preoperative examination in less developed countries may be the reason for this variation.

GBC is detected incidentally in 0.1%-0.3% of all cholecystectomies. In the present study, the incidence of incidentally diagnosed GBC was 0.32%. Selective histopathological examination is recommended by some

Table 3. Risk factors associated with gallbladder stones in pathological results

Variables	Gallbladder stone		p-value
	No	Yes	
Metaplasia	35	39	0.019
Dysplasia carcinoma	12	16	
Dysplasia	12	0	0.278
Metaplasia carcinoma	35	56	
Carcinoma	1	16	0.001
Dysplasia metaplasia	47	39	

Table 4. Comparison of malignant and premalignant lesions of the gallbladder according to ultrasonography features

US results		Metaplasia	Dysplasia	Carcinoma	p-value
Microlithiasis	Yes	20	1	6	0.3
	No	49	8	11	
Increase in wall thickening	Yes	6	1	12	0.0001
	No	63	8	5	
Multiple stones	Yes	41	1	12	0.78
	No	28	8	5	

Table 5. T stage, size, localization, histological subtype, cystic duct invasion and survival time of 17 gallbladder cancer patients

Case	Sex	T stage	Size (mm)	Localization	Histological subtype	Ductus cysticus invasion	Survival (months) (14±8.93)
1	M	Tis	30	Corpus	AC	No	Unknown [”]
2	F	T3	40	Fundus	AsC	No	6
3	F	T4	17	Corpus	AC	Yes	2
4	F	Tis	4	Corpus	AC	No	Alive
5	F	T4	24	Corpus	AC	Yes	22
6	M	T4	31	Corpus	AC	Yes	10
7	F	Tis	*	Corpus	AC	No	Deceased [†]
8	F	Tis	*	Corpus	AC	No	Alive
9	M	Tis	*	Corpus	AC	No	Alive
10	M	Tis	*	Corpus	AC	No	Alive
11	F	Tis	*	Corpus	AC	No	Alive
12	M	T4	25	Corpus	AC	Yes	19
13	M	T4	25	Fundus	AC	No	26
14	F	T1	3	Fundus	AC	No	Unknown [”]
15	F	T4	30	Corpus	AC	Yes	23
16	M	T4	21	Corpus	AC	No	4
17	F	T1	2	Fundus	AC	No	Alive

*: No information in pathology report, ”: No information about patient status, †: Died, unrelated to gallbladder cancer, AC: Adenocarcinoma, AsC: Adenosquamous carcinoma, F: Female, M: Male

authors (9,10). However, Jha et al. (11) advocated for standard histopathological examination. They found that 9 of 20 GBC cases showed no evidence of GBC in macroscopic examination. In addition, standard histopathological examination of specimens is recommended by the Royal College of Pathologists (12). A significant pathology may be found with normal gross examination, however, most GBC specimens demonstrate the same morphologic features with thickened and fibrotic walls, mucosal ulceration and nodular mucosa.

Only 30% of patients are suspected of having GBC before gallbladder surgery, and 15%-25% of them are eligible for surgical treatment (1). Expert consensus and the National Comprehensive Cancer Network guidelines recommend simple cholecystectomy for Tis and T1a GBC. For T1b or higher-grade tumors, the guidelines recommend cholecystectomy with radical liver resection, portal lymphadenectomy and resection of the common bile duct, if necessary, to obtain R0 resection (13). Over the past decades, surgical mortality has decreased, and extended resection of the gallbladder and liver segment 4b-5 has resulted in improved survival. Surprisingly, Kasumova et al. (1) revealed that simple cholecystectomy with adjuvant therapy has an advantage over extended surgical resection of the gallbladder and liver bed. Although further studies are needed on this subject, the rarity of this disease hampers the performance of prospective studies.

In the present study, premalignant and malignant lesions of the gallbladder were more frequently observed in females, but female sex was a significant

risk factor only for the development of metaplasia and not for the development of GBC. Although GBC was more frequently observed in females, female sex was not identified as a significant risk factor in our study, different from the data in the literature (7,14,15). The limited number of GBC cases in our study may be the cause of this difference. Female sex hormones may be linked to the development of premalignant and malignant lesions of the gallbladder. Estrogen increases the secretion of xenobiotics and cholesterol. Progesterone also impairs contractility of the gallbladder and prolongs gallbladder residence time of bile (16). However, further studies are needed on this subject.

Advanced age is another known risk factor for the development of GBC (17). Consistent with data in the literature, our study found that advanced age was the most important risk factor for the development of GBC (Table 2). Ahn et al. (18) found that an age 65 years or older was the only independent predictor of GBC. In a study by Hundal and Shaffer (19), metaplasia, dysplasia and carcinoma transformation in GBC was thought to have developed over a span of 5-15 years (19). Consistent with the findings of Hundal and Shaffer (19), we found that the mean age of GBC diagnosis (70.79±10.1) was almost 15 years greater than the mean age of diagnosis for metaplasia and dysplasia (54.18±13.5 and 54.63±14.2, respectively) (Table 1). Neoplastic cascade of metaplasia-dysplasia-carcinoma requires many years to develop, and this may be the reason for the higher incidence of GBC in elderly patients.

Gallstones are a well-known potential risk factor for GBC, with an 8.3% higher risk in patients with gallstones than in the general population (20). GBC develops in only 0.2%-3% of all patients with cholelithiasis (4), but gallbladder stones are present in 90% of patients with GBC (21). Waghmare and Kamat (22) reported that gallstones had a strong association with GBC. Jha et al. (11) also reported that GBC was associated with gallstones in 14 of 20 patients. A cohort study by Ryu et al. (23) also showed that gallstones were associated with increased risk of mortality in GBC. Shaffer argued that patients with gallstones larger than 3 cm had a 4% risk of developing GBC over 20 years (24). Hamdani et al. (25) reported that 86% of 198 patients diagnosed with GBC between Jan 2004 and Dec 2011 had gallstones. They supported this association by reporting that the routine scenario for GBC was elderly women with gallstones. De Aretxabala et al. (26) reported that 53 of 54 patients with resectable GBC presented with gallstones. Gallstones and chronic inflammation caused by gallstones have the potential to create metaplasia, and it was demonstrated that metaplasia in gallbladder can

Table 6. Studies assessing gallbladder cancer incidence

Studies	Duration	Place	Sample size	GBC incidence (%)
Zhang et al. (8)	1999-2007	China	10466	0.19
Glauser et al. (34)	1994-2004	Switzerland	30960	0.28
Antonakis et al. (35)	1990-2000	Greece	5539	0.19
Yi et al. (36)	1992-2009	China	14037	0.17
Koshenkov et al. (37)	1996-2011	USA	26572	0.25
Genc V et al. (38)	1999-2010	Turkey	5164	0.09
Present study	2012-2015	Turkey	5206	0.32

GBC: Gallbladder cancer

cause the development of dysplastic epithelium, which plays a role in the development of GBC (27). Wistuba and Gazdar (28) proposed multi-step pathogenesis of gallbladder cancer from gallstones to carcinoma that may take over 20 years. A review article by Shrikhande et al. (29) supports prophylactic cholecystectomy in patients with cholelithiasis in populations having a higher GBC incidence. However, some authors argue against gallstones as a potential cause of GBC. Maringhini et al. (30) reported that only five (0.19%) of 2583 patients with gallstones developed GBC. Thus, an overall cumulative GBC incidence was found to be 1% for 20 years after the initial diagnosis of gallstone in patients who did not undergo cholecystectomy. An old but valuable study by Comfort et al. reported that only 1% of silent gallstone patients developed GBC (31). Acalculous GBC cases are another source of debate. Gallbladder polyps, parasites or cholestasis are thought to be the reason for acalculous GBC. Literature data is far from establishing a causative role for cholelithiasis in the development of GBC. Most authors support the relationship between gallstones and GBC, but low GBC incidence in patients with cholelithiasis raises suspicion about this hypothesis. In our study, the presence of gallstones was found to be a risk factor for the development of metaplasia and carcinoma (Table 3).

Gallbladder wall thickening is a sign of inflammation that can be determined by ultrasonography. In ultrasonography, gallbladder carcinoma may also present with generalized mural thickening replacing gallbladder lumen. In our study, gallbladder thickening detected by ultrasonography was more frequent in carcinoma cases than in metaplasia and dysplasia cases (Table 4). Gallbladder wall thickening may be a warning sign for GBC in patients with epidemiological and genetic risk factors.

Adenocarcinoma is the most frequent subtype of gallbladder carcinomas with an incidence of 95%. It is mostly located in the fundus (60%), corpus (30%) and neck (10%) of the gallbladder (24). Epidermoid carcinoma and adenosquamous carcinoma are other rare subtypes. The most common histological subtype of adenocarcinoma is unspecified type (87.7%), followed by papillary (6.9%) and mucinous adenocarcinomas (3.8%) (25). Of the 17 cases reported by us, 16 had unspecified subtype adenocarcinoma (94.2%) and one had adenosquamous carcinoma (5.8%). In contrast with the literature, the most common location of carcinoma in our case series was the corpus of the gallbladder (Table 5). Consistent with our findings, Hamdani et al. (25) reported that the corpus was the most common location (25). In their study including

437 patients with GBC, Shindoh et al. (32) categorized the tumors as peritoneal-surface localized and hepatic-surface localized. They revealed that peritoneal-surface carcinomas had better prognosis. The reason for different location of GBC may be the limited number of GBC cases in this study.

In a study by Nakata et al. (33), cystic duct invasion was associated with poor prognosis because of high incidence of concomitant perineural invasion and lymph node metastasis. Consistent with the study by Nakata et al. (33), in our study, five of seven T4 stage cases had cystic duct invasion and all had perineural and vascular infiltration. Overall survival of these patients was 15.2 ± 8.98 years (Table 5). Patients without cystic duct invasion had better survival rates (six patients survived). However, the difference in survival between patients with and without cystic duct invasion is not significant. The limited number of GBC cases in our study may be a reason for this result.

Conclusion

GBC is one of the deadliest cancers, with a short life expectancy from the time of diagnosis. It is difficult to make a preoperative diagnosis of this cancer, and the definitive treatment is surgery. GBC should be considered particularly in individuals in the high-risk group/population, with genetic predisposition and with an increase in gallbladder wall thickening on ultrasonography and in elderly patients with gallstones. Cholecystectomy should be considered as the most effective method to prevent the development of cancer in patients of advancing age and females with gallbladder stones. The limitations of the present study include its retrospective nature and limited number of patients with GBC. Further scientific studies are needed to identify risk factors, improve early diagnosis and minimize the mortality rate of GBC.

Authorship Contributions

Concept: M.F.F., K.Ş. Design: M.F.F. Data Collection or Processing: M.F.F., K.Ş. Analysis or Interpretation: M.F.F., K.Ş., T.K. Literature Searching :A.K. Writing: M.F.F., K.Ş., A.G.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Kasumova GG, Tabatabaie O, Najarian NM, et al. Surgical Management of Gallbladder Cancer: Simple Versus Extended Cholecystectomy and the Role of Adjuvant Therapy. *Ann Surg* 2017;4:625-31.

2. Ferlay J, Soerjomataram I, Evrik M, et al. GLOBOCAN 2012 v.10, Cancer incidence and mortality Worldwide: IARC Cancer Base No:11 Lyon, France
3. Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. *World J Gastroenterol* 2017;14:3978-98.
4. Goetze TO. Gallbladder carcinoma: Prognostic factors and therapeutic options. *World J Gastroenterol* 2015;21:12211-17.
5. Lee SE, Jang JY, Lim CS, Kang MJ, Kim SW. Systematic review on surgical treatment for T1 gallbladder cancer. *World J Gastroenterol* 2011;17:174-80.
6. Eckel F, Brunner T, Jelic S; ESMO Guidelines Working Group. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010;21 Suppl 5:v65-9.
7. Izarzugaza I, Fernandez L, Forman D, Sierra MS. Burden of gallbladder cancer in Central and South America. *Cancer Epidemiol* 2016;44:82-9.
8. Zhang WJ, Xu GF, Zou XP, et al. Incidental Gallbladder Carcinoma Diagnosed During or After Laparoscopic Cholecystectomy. *World J Surg* 2009;33:2651-6.
9. Talreja V, Ali A, Khawaja R, Rani K, Samnani SS, Farid FN. Surgically resected gall bladder: Is histopathology needed for all? *Surg Res Pract* 2016. 2016 9319147.
10. Dix FP, Bruce IA, Krypczyk A, Ravi S. A selective approach to histopathology of the gallbladder is justifiable. *Surgeon* 2003;1:233-5.
11. Jha V, Sharma P, Mandal KA. Incidental gallbladder carcinoma: Utility of histopathological evaluation of routine cholecystectomy specimens. *South Asian J Cancer* 2018;7:21-3.
12. Royal college of pathologist. Histopathology of limited or no clinical value. Report of Working Group of Royal College of Pathologist 2nd ed. London, 2002
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary cancers. Version 2.2016. Available t: www.nccn.org
14. Pitt SC, Jin LX, Hall BL, Strasberg SM, Pitt HA. Incidental gallbladder cancer at cholecystectomy: when should the surgeon be suspicious? *Ann Surg* 2014;260:128-33.
15. Kayahara M, Nagakawa T, Nakagawara H, Kitagawa H, Ohta T. Prognostic factors for gallbladder cancer in Japan. *Ann Surg* 2008;248:807-14.
16. Pilgrim CH, Groeschl RT, Christians KK, et al. Modern perspectives on factors predisposing to the development of gallbladder cancer. *HPB (Oxford)* 2013;15 839-44.
17. Gupta S, Kori C, Kumar V, et al. Epidemiological study of gallbladder cancer. Patients from North Indian Gangetic Planes- A high volume centre's experience. *J Gastrointest Canc* 2016;47:27-35.
18. Ahn Y, Park CS, Hwang S, Jang HJ, Choi KM, Lee SG. Incidental gallbladder cancer after routine cholecystectomy: when should we suspect it preoperatively and what are predictors of patient survival? *Ann Surg Treat Res* 2016;90:131-8.
19. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. *Clin Epidemiol* 2014;6:99-109.
20. Kanthan K, Senger JL, Ahmed S, et al. Gallbladder cancer in the 21st century. *J Oncol* 2015:967472.
21. Ghimire P, Yogi N, Shrestha BB. Incidence of incidental carcinoma gallbladder in cases of routine cholecystectomy. *Kathmandu University Med Journal* 2011;34:3-6.
22. Waghmare RS, Kamat RN. Incidental Gall Bladder Carcinoma in Patients Undergoing Cholecystectomy: A Report of 7 Cases. *J Assoc Physicians India* 2014;62:793-6.
23. Ryu S, Chang Y, Yun KE, Jung HS, Shin JH, Shin H. Gallstones and the Risk of Gallbladder Cancer Mortality: A Cohort Study. *Am J Gastroenterol* 2016;111:1476-87.
24. Shaffer EA. Gallbladder Cancer The Basics. *Gastroenterol Hepatol* 2008;4:737-41.
25. Hamdani NH, Qadri SK, Aggarwalla R, et al. Clinicopathological Study of Gall Bladder Carcinoma with Special Reference to Gallstones: Our 8-year Experience from Eastern India. *Asian Pac J Cancer Prev* 2012;13:5613-7.
26. de Aretxabala X, I Roa, L Burgos, et al. Gallbladder cancer in Chile: A report on 54 potentially resectable tumors. *Cancer* 1992;69:60-5.
27. Seretis C, Lagoudianakis E, Gemenetis G, et al. Metaplastic Changes in Chronic Cholecystitis: Implications for Early Diagnosis and Surgical Intervention to Prevent the Gallbladder Metaplasia-Dysplasia-Carcinoma Sequence. *J Clin Med Res* 2014;6:26-9.
28. Wistuba II, Gazdar AF. Gallbladder cancer: Lessons from a rare tumour. *Nat Rev Cancer* 2004;4:695-706.
29. Shrikhande SV, Barreto SG, Singh S, et al. Cholelithiasis in gallbladder cancer: Coincidence, cofactor, or cause! *Eur J Surg Oncol* 2010;36: 514-19.
30. Maringhini A, Moreau JA, Melton LJ 3rd, Hench VS, Zinsmeister AR, DiMagno EP. Gallstones, gallbladder cancer, and other gastrointestinal malignancies. An epidemiologic study in Rochester, Minnesota. *Ann Intern Med* 1987;107:30-5.
31. Comfort MW, Gray HK, Wilson JM. The silent gallstones: a 10-20 year follows up. *Ann Surg* 1948;128:931-6.
32. Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. *Ann Surg* 2015;261:733-9
33. Nakata T, Kobayashi A, Miwa S, et al. Impact of Tumor Spread to the Cystic Duct on the Prognosis of Patients with Gallbladder Carcinoma. *World J Surg* 2007;31:155-61.